Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedSep 16, 2026
DataAggregated Company Financials
Companies20
  • 7D-4.9%
  • 3M-0.3%
  • 1Y-19.6%
  • YTD-14.2%

Over the last 7 days, the Healthcare industry has dropped 5.3%, driven by a pullback from Novo Nordisk of 5.5%. The industry has fallen 18% in the last year. As for the next few years, earnings are expected to grow by 4.3% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 16 Sep 2026DKK 1.7tDKK 468.4bDKK 137.4b22.6x12.1x3.6x
Fri, 14 Aug 2026DKK 1.8tDKK 473.9bDKK 141.5b21.7x12.5x3.7x
Sun, 12 Jul 2026DKK 1.9tDKK 469.2bDKK 147.1b20.6x12.6x4x
Tue, 09 Jun 2026DKK 1.6tDKK 468.9bDKK 147.1b19.7x11x3.5x
Thu, 07 May 2026DKK 1.7tDKK 466.4bDKK 149.5b20.7x11.5x3.7x
Sat, 04 Apr 2026DKK 1.5tDKK 447.8bDKK 130.0b17.4x11.3x3.3x
Mon, 02 Mar 2026DKK 1.5tDKK 447.7bDKK 130.9b18.7x11.5x3.3x
Wed, 28 Jan 2026DKK 2.2tDKK 453.1bDKK 136.7b17.9x16.5x5x
Fri, 26 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Sun, 23 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b17.1x13.5x4.1x
Tue, 21 Oct 2025DKK 2.1tDKK 447.6bDKK 141.7b19.1x14.9x4.7x
Thu, 18 Sep 2025DKK 2.1tDKK 447.1bDKK 141.6b18.9x15x4.8x
Sat, 16 Aug 2025DKK 1.9tDKK 444.4bDKK 140.3b28.1x13.6x4.3x
Mon, 14 Jul 2025DKK 2.4tDKK 423.1bDKK 124.5b29.9x19.3x5.7x
Wed, 11 Jun 2025DKK 2.8tDKK 423.7bDKK 124.7b31.2x22.4x6.6x
Fri, 09 May 2025DKK 2.3tDKK 422.8bDKK 124.7b21.4x18.8x5.5x
Sun, 06 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b22.8x19.4x5.8x
Tue, 04 Mar 2025DKK 3.4tDKK 410.0bDKK 121.4b28x27.8x8.2x
Thu, 30 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b28.9x29.2x8.4x
Sat, 28 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Mon, 25 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x34.9x10x
Wed, 23 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b35.4x38.6x11.1x
Fri, 20 Sep 2024DKK 4.6tDKK 371.9bDKK 107.1b36.7x42.9x12.4x
Sun, 18 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.2x43.9x12.7x
Tue, 16 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.2x13.8x
Thu, 13 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.4x46.3x13.9x
Sat, 11 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Mon, 08 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.7x13x
Wed, 06 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38.2x44.6x13x
Fri, 02 Feb 2024DKK 4.0tDKK 320.8bDKK 90.1b32x44.7x12.6x
Sun, 31 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Tue, 28 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b33.2x40.9x11.5x
Thu, 26 Oct 2023DKK 3.6tDKK 305.6bDKK 82.3b26.6x43.4x11.7x
Sat, 23 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Price to Earnings Ratio

41.3x


Total Market Cap: DKK 3.4tTotal Earnings: DKK 82.2bTotal Revenue: DKK 305.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 27.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.3x which is lower than its 3-year average PE of 27.3x.
  • The 3-year average PS ratio of 8.0x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-3.34%
Healthcare-4.94%
Healthcare Services-1.49%
Biotech-1.81%
Medical Equipment-3.17%
Healthtech-4.70%
Pharma-5.52%
Life Sciences-8.87%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 30.6x.
    • Analysts are expecting annual earnings growth of 51.5%, which is higher than its past year's earnings growth of 8.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DEMANT DemantDKK 295.801.1%
+DKK 674.9m		23.8%PE25.7x
STENO StenocareDKK 0.931.3%
+DKK 518.4k		-11.6%PS3.5x

Latest News

HLUN B
DKK 41.62
H. Lundbeck
7D
-5.2%
1Y
-3.7%
ZEAL
DKK 277.20
Zealand Pharma
7D
-6.8%
1Y
-35.1%
NOVO B
DKK 275.90
Novo Nordisk
7D
-5.5%
1Y
-23.2%
GMAB
DKK 2,150.00
Genmab
7D
-0.7%
1Y
21.2%
Narrative Update • Sep 07

GMAB: Pipeline Progress Will Address Darzalex Cliff And Support 2026 Catalysts

Genmab's updated analyst fair value moves from DKK 2,392 to DKK 2,454 as analysts lift price targets toward DKK 2,500 on expectations that the broader pipeline can help manage the Darzalex patent cliff, while recent trial readouts support using a lower future P/E multiple and slightly more cautious revenue growth and margin assumptions. Analyst Commentary Recent commentary on Genmab shows a clear tilt toward optimism, with several bullish analysts lifting price targets in both DKK and US$ terms and highlighting progress across the pipeline.
COLO B
DKK 419.70
Coloplast
7D
-6.0%
1Y
-29.7%
GUBRA
DKK 296.80
Gubra
7D
-14.9%
1Y
-25.9%
New Narrative • Sep 04

Obesity And Metabolic Tailwinds Will Drive Powerful Long Term Upside Potential

Catalysts About Gubra Gubra focuses on peptide drug discovery, obesity and metabolic disease research, supported by an in-house CRO and venture investment platform. What are the underlying business or industry changes driving this perspective?
DEMANT
DKK 295.80
Demant
7D
1.1%
1Y
23.8%
Narrative Update • Sep 03

DEMANT: Future Hearing Portfolio And Mixed Ratings Will Support Further Upside

The analyst price target for Demant has been revised from DKK 345 to about DKK 375, with analysts pointing to updated fair value work that reflects Street research highlighting higher DKK-based targets alongside expectations for slightly stronger revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on Demant points to a mix of optimism and caution, with several bullish analysts lifting price targets and a few others stepping back on rating.
BAVA
DKK 200.40
Bavarian Nordic
7D
-4.5%
1Y
-13.6%
ALK B
DKK 192.30
ALK-Abelló
7D
-6.0%
1Y
-7.1%
STENO
DKK 0.93
Stenocare
7D
1.3%
1Y
-11.6%